Binding thermodynamics of statins to HMG-CoA reductase

被引:81
作者
Carbonell, T [1 ]
Freire, E [1 ]
机构
[1] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA
关键词
D O I
10.1021/bi050905v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The statins are powerful inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase), the key enzyme in the cholesterol biosynthetic pathway, and are among the most widely prescribed drugs in the world. Despite their clinical importance, little is known about the binding thermodynamics of statins to HMG-CoA reductase. In this paper, we report the results of inhibition kinetics and microcalorimetric analysis of a representative type I statin (pravastatin) and four type II statins (fluvastatin, cerivastatin, atorvastatin, and rosuvastatin). Inhibition constants (K) range from 2 to 250 nM for the different statins. Isothermal titration calorimetry (ITC) experiments yield binding enthalpies (Delta H-binding) ranging between zero and -9.3 kcal/mol at 25 degrees C. There is a clear correlation between binding affinity and binding enthalpy: the most powerful statins bind with the strongest enthalpies. The proportion by which the binding enthalpy contributes to the binding affinity is not the same for all statins, indicating that the balance among hydrogen bonding, van der Waals, and hydrophobic interactions is not the same for all of them. At 25 degrees C, the dominant contribution to the binding affinity of fluvastatin, pravastatin, cerivastatin, and atorvastatin is the entropy change. Only for rosuvastatin does the enthalpy change contribute more than 50 % of the total binding energy (76 %). Since the enthalpic and entropic contributions to binding originate from different types of interactions, the thermodynamic dissection presented here provides a way to identify interactions that are critical for affinity and specificity.
引用
收藏
页码:11741 / 11748
页数:8
相关论文
共 43 条
[11]   Beneficial cardiovascular pleiotropic effects of statins [J].
Davignon, J .
CIRCULATION, 2004, 109 (23) :39-43
[12]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[13]   Factorising ligand affinity:: A combined thermodynamic and crystallographic study of trypsin and thrombin inhibition [J].
Dullweber, F ;
Stubbs, MT ;
Musil, D ;
Stürzebecher, J ;
Klebe, G .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 313 (03) :593-614
[14]   SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE EXPRESSED IN ESCHERICHIA-COLI - PRODUCTION OF HOMOGENEOUS PROTEIN [J].
FRIMPONG, K ;
DARNAY, BG ;
RODWELL, VW .
PROTEIN EXPRESSION AND PURIFICATION, 1993, 4 (04) :337-344
[15]  
Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO
[16]  
2-F
[17]   Quality of care for secondary prevention for patients with coronary heart disease: Results of the Hastening the Effective Application of Research through Technology (HEART) trial [J].
Goff, DC ;
Gu, L ;
Cantley, LK ;
Sheedy, DJ ;
Cohen, SJ .
AMERICAN HEART JOURNAL, 2003, 146 (06) :1045-1051
[18]   Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].
Graham, DJ ;
Staffa, JA ;
Shatin, D ;
Andrade, SE ;
Schech, SD ;
La Grenade, L ;
Gurwitz, JH ;
Chan, KA ;
Goodman, MJ ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590
[19]   Prevention and rehabilitation - Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study [J].
Hague, W ;
Forder, P ;
Simes, J ;
Hunt, D ;
Tonkin, A .
AMERICAN HEART JOURNAL, 2003, 145 (04) :643-651
[20]   Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors [J].
Hamelin, BA ;
Turgeon, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (01) :26-37